Loading...
•
Dec 31, 2019
Guardant Health Q4 2019 Earnings Report
Reported a revenue increase driven by precision oncology testing and development services.
Key Takeaways
Guardant Health reported a strong fourth quarter and full year 2019, with Q4 revenue reaching $62.9 million, a 91% increase year-over-year. The company's full year revenue grew by 137% compared to 2018. They also provided full year 2020 revenue guidance of $275.0 million to $285.0 million.
Revenue of $62.9 million for the fourth quarter, a 91% increase year-over-year.
Full year 2019 revenue of $214.4 million, a 137% increase year-over-year.
Received expanded Medicare local coverage determination for Guardant360 assay.
Initiated the NRG-GI005 COBRA study to validate the clinical utility of LUNAR-1 assay.
Guardant Health
Guardant Health
Guardant Health Revenue by Segment
Revenue by Segment
Oncology Revenue
CapyFin.com Forward Guidance
Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million and net loss to be in the range of $155.0 million to $160.0 million.
Positive Outlook
- Full year 2020 revenue to be in the range of $275.0 million to $285.0 million.
- Representing 31% growth over the full year 2019 at the midpoint of the range.
Challenges Ahead
- Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020.